1                                              HLRCC is associated with clinically significant uterine

2                                              HLRCC-associated tumors harbor biallelic FH inactivation

3 rate that inactivating mutations of FH in an HLRCC-derived cell line result in glucose-mediated gener

4 basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it i

5 ider that the study of rare diseases such as HLRCC, combining analyses of human tumours and cell line

6 ditary leiomyomatosis and renal cell cancer (HLRCC) is an autosomal dominant disorder characterized b

7 ditary leiomyomatosis and renal cell cancer (HLRCC) is an inherited cancer syndrome linked to biallel

8 ditary leiomyomatosis and renal cell cancer (HLRCC), and recently, FH mutations have been detected in

9 ditary leiomyomatosis and renal cell cancer (HLRCC), characterised by benign smooth muscle cutaneous

10 ditary leiomyomatosis and renal cell cancer (HLRCC), implicated FH, a gene on chromosome 1q43 encodin

11 viduals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas an

12 ditary leiomyomatosis and renal cell cancer (HLRCC).

13 ditary leiomyomatosis and renal-cell cancer (HLRCC).

14  hereditary leiomyomatosis and renal cancer (HLRCC) syndrome, and have shown that these cancers may h

15                       Consistently, clinical HLRCC tissues showed increased expression levels of both

16 s supports it as the susceptibility gene for HLRCC, its role in families in North America has not bee

17 at the obligate glycolytic switch present in HLRCC is critical to HIF stabilization via ROS generatio

18 roviding a new potential target for treating HLRCC patients.

19 ows that mutations in FH are associated with HLRCC in North America.

20 enal tumors and FH mutations associated with HLRCC.

21                             Individuals with HLRCC are at risk to develop cutaneous and uterine leiom